Literature DB >> 31078626

Encapsulation of proteins from Leishmania panamensis into PLGA particles by a single emulsion-solvent evaporation method.

Juan David Ospina-Villa1, Catalina Gómez-Hoyos2, Robin Zuluaga-Gallego3, Omar Triana-Chávez4.   

Abstract

The current therapy for the treatment of leishmaniasis is unsatisfactory because it has multiple side effects, and resistance has been reported among the parasites that cause these diseases. Numerous efforts have been made to develop new candidates for vaccines. In recent years, particles of biodegradable polymers have been proposed as vehicles to transport and protect antigens, proteins, drugs and vaccines. In this work, the oil/water (o/w) single emulsion-solvent evaporation technique was used to prepare PLGA biodegradable particles. The encapsulation of two hypothetical proteins from Leishmania panamensis was performed to validate the proposed method. For this validation, different concentrations (50, 100, 150, 200, 250, 500, and 750 μg/ml) of both proteins were encapsulated into PLGA particles, and the particle sizes and shapes were evaluated by optical microscopy and scanning electron microscopy (SEM), respectively. The release of proteins was confirmed by SDS-PAGE and Western blot analyses. The integrity of both proteins was conserved, and they were released from day one until day 15, with a maximum amount of 46 ± 4.25% for the LpanUA.27.1260 protein and 26.19 ± 3.41% for LpanUA.22.1860. Additionally, the protective efficacy of one of these encapsulated proteins was evaluated in vivo using BALB/c mice infected with L. panamensis. Therefore, the encapsulation of proteins is presented here as an excellent alternative to evaluate the antigenicity of proteins from parasites of medical importance such as L. panamensis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biodegradable polymers; Encapsulated microparticles; Hypothetical proteins; Leishmania; Vaccine

Mesh:

Substances:

Year:  2019        PMID: 31078626     DOI: 10.1016/j.mimet.2019.05.004

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN: 0167-7012            Impact factor:   2.363


  6 in total

Review 1.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

2.  Characterization of the Shells in Layer-By-Layer Nanofunctionalized Particles: A Computational Study.

Authors:  E Barchiesi; T Wareing; L Desmond; A N Phan; P Gentile; G Pontrelli
Journal:  Front Bioeng Biotechnol       Date:  2022-06-30

3.  Combined delivery of salinomycin and docetaxel by dual-targeting gelatinase nanoparticles effectively inhibits cervical cancer cells and cancer stem cells.

Authors:  Qin Wang; Ying-Tzu Yen; Chen Xie; Fangcen Liu; Qin Liu; Jia Wei; Lixia Yu; Lifeng Wang; Fanyan Meng; Rutian Li; Baorui Liu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 4.  PLGA-Based Composites for Various Biomedical Applications.

Authors:  Cátia Vieira Rocha; Victor Gonçalves; Milene Costa da Silva; Manuel Bañobre-López; Juan Gallo
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

5.  Electrospun PLGA Fiber Diameter and Alignment of Tendon Biomimetic Fleece Potentiate Tenogenic Differentiation and Immunomodulatory Function of Amniotic Epithelial Stem Cells.

Authors:  Mohammad El Khatib; Annunziata Mauro; Miriam Di Mattia; Ralf Wyrwa; Martina Schweder; Massimo Ancora; Francesco Lazzaro; Paolo Berardinelli; Luca Valbonetti; Oriana Di Giacinto; Andrea Polci; Cesare Cammà; Matthias Schnabelrauch; Barbara Barboni; Valentina Russo
Journal:  Cells       Date:  2020-05-13       Impact factor: 6.600

6.  Encapsulation of Amikacin into Microparticles Based on Low-Molecular-Weight Poly(lactic acid) and Poly(lactic acid-co-polyethylene glycol).

Authors:  Marta Glinka; Katerina Filatova; Justyna Kucińska-Lipka; Eva Domincova Bergerova; Andrzej Wasik; Vladimir Sedlařík
Journal:  Mol Pharm       Date:  2021-07-01       Impact factor: 4.939

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.